Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance
to the standard chemotherapeutic agent, temozolomide (TMZ). Promoter methylation of the …

Methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter has
emerged as strong prognostic factor in the therapy of glioblastoma multiforme. It is …

Despite multimodality treatment protocol including surgical resection, radiotherapy, and
chemotherapy in patients with glioblastoma multiforme (GBM), most suffer from treatment …

MGMT promoter methylation is related to the increased sensitivity of tumour tissue to
chemotherapy with temozolomide (TMZ) and thus to improved patient survival. However, it is …

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes
temozolomide-induced alkylation, thereby preventing DNA damage and cytotoxicity. We …

Background We analyzed prospectively whether MGMT (O6-methylguanine-DNA
methyltransferase) mRNA expression gains prognostic/predictive impact independent of …

Background: The DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT)
confers therapeutic resistance to DNA alkylating agents, including temozolomide. It is largely …

Abstract BACKGROUND: O6‐methylguanine‐DNA methyltransferase (MGMT) is a key
enzyme in the DNA repair process after alkylating agent action. Epigenetic silencing of the …

Resistance to alkylating agents via direct DNA repair by O6-methylguanine
methyltransferase (MGMT) remains a significant barrier to the successful treatment of …

Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma
multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair …